Frequent inactivation of A20 in B-cell lymphomas

Motohiro Kato, Masashi Sanada, Itaru Kato, Yasuharu Sato, Junko Takita, Kengo Takeuchi, Akira Niwa, Yuyan Chen, Kumi Nakazaki, Junko Nomoto, Yoshitaka Asakura, Satsuki Muto, Azusa Tamura, Mitsuru Iio, Yoshiki Akatsuka, Yasuhide Hayashi, Hiraku Mori, Takashi Igarashi, Mineo Kurokawa, Shigeru ChibaShigeo Mori, Yuichi Ishikawa, Koji Okamoto, Kensei Tobinai, Hitoshi Nakagama, Tatsutoshi Nakahata, Tadashi Yoshino, Yukio Kobayashi, Seishi Ogawa

Research output: Contribution to journalArticle

389 Citations (Scopus)

Abstract

A20 is a negative regulator of the NF-B pathway and was initially identified as being rapidly induced after tumour-necrosis factor-α stimulation. It has a pivotal role in regulation of the immune response and prevents excessive activation of NF-B in response to a variety of external stimuli; recent genetic studies have disclosed putative associations of polymorphic A20 (also called TNFAIP3) alleles with autoimmune disease risk. However, the involvement of A20 in the development of human cancers is unknown. Here we show, using a genome-wide analysis of genetic lesions in 238 B-cell lymphomas, that A20 is a common genetic target in B-lineage lymphomas. A20 is frequently inactivated by somatic mutations and/or deletions in mucosa-associated tissue lymphoma (18 out of 87; 21.8%) and Hodgkins lymphoma of nodular sclerosis histology (5 out of 15; 33.3%), and, to a lesser extent, in other B-lineage lymphomas. When re-expressed in a lymphoma-derived cell line with no functional A20 alleles, wild-type A20, but not mutant A20, resulted in suppression of cell growth and induction of apoptosis, accompanied by downregulation of NF-B activation. The A20-deficient cells stably generated tumours in immunodeficient mice, whereas the tumorigenicity was effectively suppressed by re-expression of A20. In A20-deficient cells, suppression of both cell growth and NF-B activity due to re-expression of A20 depended, at least partly, on cell-surface-receptor signalling, including the tumour-necrosis factor receptor. Considering the physiological function of A20 in the negative modulation of NF-B activation induced by multiple upstream stimuli, our findings indicate that uncontrolled signalling of NF-B caused by loss of A20 function is involved in the pathogenesis of subsets of B-lineage lymphomas.

Original languageEnglish
Pages (from-to)712-716
Number of pages5
JournalNature
Volume459
Issue number7247
DOIs
Publication statusPublished - 04-06-2009
Externally publishedYes

Fingerprint

B-Cell Lymphoma
Lymphoma
Alleles
Sequence Deletion
Tumor Necrosis Factor Receptors
Cell Surface Receptors
Human Development
Sclerosis
Growth
Hodgkin Disease
Autoimmune Diseases
Neoplasms
Histology
Mucous Membrane
Down-Regulation
Tumor Necrosis Factor-alpha
Genome
Apoptosis
Cell Line

All Science Journal Classification (ASJC) codes

  • General

Cite this

Kato, M., Sanada, M., Kato, I., Sato, Y., Takita, J., Takeuchi, K., ... Ogawa, S. (2009). Frequent inactivation of A20 in B-cell lymphomas. Nature, 459(7247), 712-716. https://doi.org/10.1038/nature07969
Kato, Motohiro ; Sanada, Masashi ; Kato, Itaru ; Sato, Yasuharu ; Takita, Junko ; Takeuchi, Kengo ; Niwa, Akira ; Chen, Yuyan ; Nakazaki, Kumi ; Nomoto, Junko ; Asakura, Yoshitaka ; Muto, Satsuki ; Tamura, Azusa ; Iio, Mitsuru ; Akatsuka, Yoshiki ; Hayashi, Yasuhide ; Mori, Hiraku ; Igarashi, Takashi ; Kurokawa, Mineo ; Chiba, Shigeru ; Mori, Shigeo ; Ishikawa, Yuichi ; Okamoto, Koji ; Tobinai, Kensei ; Nakagama, Hitoshi ; Nakahata, Tatsutoshi ; Yoshino, Tadashi ; Kobayashi, Yukio ; Ogawa, Seishi. / Frequent inactivation of A20 in B-cell lymphomas. In: Nature. 2009 ; Vol. 459, No. 7247. pp. 712-716.
@article{3a3073478a4b480eba1be90383a36d73,
title = "Frequent inactivation of A20 in B-cell lymphomas",
abstract = "A20 is a negative regulator of the NF-B pathway and was initially identified as being rapidly induced after tumour-necrosis factor-α stimulation. It has a pivotal role in regulation of the immune response and prevents excessive activation of NF-B in response to a variety of external stimuli; recent genetic studies have disclosed putative associations of polymorphic A20 (also called TNFAIP3) alleles with autoimmune disease risk. However, the involvement of A20 in the development of human cancers is unknown. Here we show, using a genome-wide analysis of genetic lesions in 238 B-cell lymphomas, that A20 is a common genetic target in B-lineage lymphomas. A20 is frequently inactivated by somatic mutations and/or deletions in mucosa-associated tissue lymphoma (18 out of 87; 21.8{\%}) and Hodgkins lymphoma of nodular sclerosis histology (5 out of 15; 33.3{\%}), and, to a lesser extent, in other B-lineage lymphomas. When re-expressed in a lymphoma-derived cell line with no functional A20 alleles, wild-type A20, but not mutant A20, resulted in suppression of cell growth and induction of apoptosis, accompanied by downregulation of NF-B activation. The A20-deficient cells stably generated tumours in immunodeficient mice, whereas the tumorigenicity was effectively suppressed by re-expression of A20. In A20-deficient cells, suppression of both cell growth and NF-B activity due to re-expression of A20 depended, at least partly, on cell-surface-receptor signalling, including the tumour-necrosis factor receptor. Considering the physiological function of A20 in the negative modulation of NF-B activation induced by multiple upstream stimuli, our findings indicate that uncontrolled signalling of NF-B caused by loss of A20 function is involved in the pathogenesis of subsets of B-lineage lymphomas.",
author = "Motohiro Kato and Masashi Sanada and Itaru Kato and Yasuharu Sato and Junko Takita and Kengo Takeuchi and Akira Niwa and Yuyan Chen and Kumi Nakazaki and Junko Nomoto and Yoshitaka Asakura and Satsuki Muto and Azusa Tamura and Mitsuru Iio and Yoshiki Akatsuka and Yasuhide Hayashi and Hiraku Mori and Takashi Igarashi and Mineo Kurokawa and Shigeru Chiba and Shigeo Mori and Yuichi Ishikawa and Koji Okamoto and Kensei Tobinai and Hitoshi Nakagama and Tatsutoshi Nakahata and Tadashi Yoshino and Yukio Kobayashi and Seishi Ogawa",
year = "2009",
month = "6",
day = "4",
doi = "10.1038/nature07969",
language = "English",
volume = "459",
pages = "712--716",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7247",

}

Kato, M, Sanada, M, Kato, I, Sato, Y, Takita, J, Takeuchi, K, Niwa, A, Chen, Y, Nakazaki, K, Nomoto, J, Asakura, Y, Muto, S, Tamura, A, Iio, M, Akatsuka, Y, Hayashi, Y, Mori, H, Igarashi, T, Kurokawa, M, Chiba, S, Mori, S, Ishikawa, Y, Okamoto, K, Tobinai, K, Nakagama, H, Nakahata, T, Yoshino, T, Kobayashi, Y & Ogawa, S 2009, 'Frequent inactivation of A20 in B-cell lymphomas', Nature, vol. 459, no. 7247, pp. 712-716. https://doi.org/10.1038/nature07969

Frequent inactivation of A20 in B-cell lymphomas. / Kato, Motohiro; Sanada, Masashi; Kato, Itaru; Sato, Yasuharu; Takita, Junko; Takeuchi, Kengo; Niwa, Akira; Chen, Yuyan; Nakazaki, Kumi; Nomoto, Junko; Asakura, Yoshitaka; Muto, Satsuki; Tamura, Azusa; Iio, Mitsuru; Akatsuka, Yoshiki; Hayashi, Yasuhide; Mori, Hiraku; Igarashi, Takashi; Kurokawa, Mineo; Chiba, Shigeru; Mori, Shigeo; Ishikawa, Yuichi; Okamoto, Koji; Tobinai, Kensei; Nakagama, Hitoshi; Nakahata, Tatsutoshi; Yoshino, Tadashi; Kobayashi, Yukio; Ogawa, Seishi.

In: Nature, Vol. 459, No. 7247, 04.06.2009, p. 712-716.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Frequent inactivation of A20 in B-cell lymphomas

AU - Kato, Motohiro

AU - Sanada, Masashi

AU - Kato, Itaru

AU - Sato, Yasuharu

AU - Takita, Junko

AU - Takeuchi, Kengo

AU - Niwa, Akira

AU - Chen, Yuyan

AU - Nakazaki, Kumi

AU - Nomoto, Junko

AU - Asakura, Yoshitaka

AU - Muto, Satsuki

AU - Tamura, Azusa

AU - Iio, Mitsuru

AU - Akatsuka, Yoshiki

AU - Hayashi, Yasuhide

AU - Mori, Hiraku

AU - Igarashi, Takashi

AU - Kurokawa, Mineo

AU - Chiba, Shigeru

AU - Mori, Shigeo

AU - Ishikawa, Yuichi

AU - Okamoto, Koji

AU - Tobinai, Kensei

AU - Nakagama, Hitoshi

AU - Nakahata, Tatsutoshi

AU - Yoshino, Tadashi

AU - Kobayashi, Yukio

AU - Ogawa, Seishi

PY - 2009/6/4

Y1 - 2009/6/4

N2 - A20 is a negative regulator of the NF-B pathway and was initially identified as being rapidly induced after tumour-necrosis factor-α stimulation. It has a pivotal role in regulation of the immune response and prevents excessive activation of NF-B in response to a variety of external stimuli; recent genetic studies have disclosed putative associations of polymorphic A20 (also called TNFAIP3) alleles with autoimmune disease risk. However, the involvement of A20 in the development of human cancers is unknown. Here we show, using a genome-wide analysis of genetic lesions in 238 B-cell lymphomas, that A20 is a common genetic target in B-lineage lymphomas. A20 is frequently inactivated by somatic mutations and/or deletions in mucosa-associated tissue lymphoma (18 out of 87; 21.8%) and Hodgkins lymphoma of nodular sclerosis histology (5 out of 15; 33.3%), and, to a lesser extent, in other B-lineage lymphomas. When re-expressed in a lymphoma-derived cell line with no functional A20 alleles, wild-type A20, but not mutant A20, resulted in suppression of cell growth and induction of apoptosis, accompanied by downregulation of NF-B activation. The A20-deficient cells stably generated tumours in immunodeficient mice, whereas the tumorigenicity was effectively suppressed by re-expression of A20. In A20-deficient cells, suppression of both cell growth and NF-B activity due to re-expression of A20 depended, at least partly, on cell-surface-receptor signalling, including the tumour-necrosis factor receptor. Considering the physiological function of A20 in the negative modulation of NF-B activation induced by multiple upstream stimuli, our findings indicate that uncontrolled signalling of NF-B caused by loss of A20 function is involved in the pathogenesis of subsets of B-lineage lymphomas.

AB - A20 is a negative regulator of the NF-B pathway and was initially identified as being rapidly induced after tumour-necrosis factor-α stimulation. It has a pivotal role in regulation of the immune response and prevents excessive activation of NF-B in response to a variety of external stimuli; recent genetic studies have disclosed putative associations of polymorphic A20 (also called TNFAIP3) alleles with autoimmune disease risk. However, the involvement of A20 in the development of human cancers is unknown. Here we show, using a genome-wide analysis of genetic lesions in 238 B-cell lymphomas, that A20 is a common genetic target in B-lineage lymphomas. A20 is frequently inactivated by somatic mutations and/or deletions in mucosa-associated tissue lymphoma (18 out of 87; 21.8%) and Hodgkins lymphoma of nodular sclerosis histology (5 out of 15; 33.3%), and, to a lesser extent, in other B-lineage lymphomas. When re-expressed in a lymphoma-derived cell line with no functional A20 alleles, wild-type A20, but not mutant A20, resulted in suppression of cell growth and induction of apoptosis, accompanied by downregulation of NF-B activation. The A20-deficient cells stably generated tumours in immunodeficient mice, whereas the tumorigenicity was effectively suppressed by re-expression of A20. In A20-deficient cells, suppression of both cell growth and NF-B activity due to re-expression of A20 depended, at least partly, on cell-surface-receptor signalling, including the tumour-necrosis factor receptor. Considering the physiological function of A20 in the negative modulation of NF-B activation induced by multiple upstream stimuli, our findings indicate that uncontrolled signalling of NF-B caused by loss of A20 function is involved in the pathogenesis of subsets of B-lineage lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=66649112854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66649112854&partnerID=8YFLogxK

U2 - 10.1038/nature07969

DO - 10.1038/nature07969

M3 - Article

C2 - 19412163

AN - SCOPUS:66649112854

VL - 459

SP - 712

EP - 716

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7247

ER -

Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009 Jun 4;459(7247):712-716. https://doi.org/10.1038/nature07969